E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
A persistent cough, the cause of which is unknown. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066656 |
E.1.2 | Term | Chronic cough |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effectiveness of XEN-D0501 over placebo in reducing objective daytime cough frequency. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effectiveness of XEN-D0501 over placebo using: - capsaicin cough responses, - objective 24-hour cough frequency, - hourly change in cough frequency, - cough severity (via visual analogue scale [VAS]), - urge to cough (via VAS) - global rating of change scale, - Leicester Cough Questionnaire (LCQ), |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female patients aged 18 years or over with chronic idiopathic cough, defined as: a) Attending a specialist cough clinic with a history of cough for more than 8 weeks b) Idiopathic cough (defined as a cough for which no objective evidence of an underlying trigger can be determined after investigation) or treatment-resistant cough (defined as a cough that is unresponsive to 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip). 2. Normal chest radiography i.e., chest X-ray or CT thorax, prior to the study (within 12 months of Visit 1) 3. Normal spirometry (i.e. forced expiratory volume in 1 second [FEV1] >80% predicted) 4. Day time cough frequency >1.5 coughs/hour (from 24-hour cough monitor at Visit 3), 5. Emax from capsaicin challenge >10 coughs (from challenge cough monitor at Visit 3), 6. Women must be of non-child bearing potential. a) Non-child bearing potential is defined as amenorrhoeic for at least 1 year AND, if aged under 60 years, have serum follicle stimulating hormone [FSH] level of at least 30 IU/L or have undergone a hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable). Women who are taking hormone replacement therapy (HRT) do not have to have FSH assessments, but the amenorrhea (before starting HRT) must have been naturally (spontaneously) occurring and have been accompanied by an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). b) If female partners of male patients are of childbearing potential, the patient must be willing to use contraception (e.g. condoms plus spermicide) AND their female partner must also be using contraception (e.g. hormonal or intra-uterine device). This double contraception must be used from the first dose of study drug until at least 90 days after the last dose of study drug. 7. Written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Body Mass Index (BMI) >35 kg/m2, 2. Current smokers or patients with urine cotinine ≥500 ng/mL, 3. Ex-smoker of <6 months, 4. Cumulative smoking history of ≥10 pack years 5. Upper respiratory tract infection within the last 6 weeks prior to randomisation (Visit 3), 6. Feverish illness within the last 1 week prior to randomisation (Visit 3), 7. Concomitant medications which may influence cough or interact with study drugs e.g. opioids, gabapentin, pregabalin, amitriptyline, ACE inhibitors, potent CYP3A4 inhibitors (such as ketoconazole, clarithromycin or HIV protease inhibitors) and systemic corticosteroids (use of local injectable, topical or inhaled corticosteroids is permitted), 8. Patients with concomitant conditions which may influence the cough reflex or the patient’s ability to participate in the study e.g. diabetes, cerebrovascular disease, Parkinson’s disease, 9. History of drug or alcohol dependency or abuse within approximately the last year prior to screening (Visit 1), 10. Regular alcohol consumption; >21 units/week for males, or >14 units/week for females, during the study (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine), 11. Any known allergy to the study drugs, 12. Pregnant and/or lactating women, 13. History or evidence of urinary retention, bladder outlet obstruction or benign prostatic hypertrophy, 14. Any clinically significant abnormalities in haematology or clinical biochemistry tests prior to randomisation (Visit 3), 15. Serum alanine transaminase (ALT), aspartate transaminase (AST) or gamma-glutamyl transpeptidase (GGT) greater than twice the upper limit of normal (ULN) at Visit 1, 16. Total serum bilirubin >1.5x ULN at Visit 1, 17. History of any kind of cancer within the last 5 years unless non-invasive, in remission and approved in writing by Sponsor, 18. Evidence of any other clinically significant disease or condition which in the opinion of the investigator would preclude the patient’s participation in this study, 19. QTcF value at Visit 1 (mean) of >450 msec (males) or >470 msec (females), 20. Patients with uncontrolled hypertension, systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg at Visit 1 (mean) or Visit 2, 21. Received investigational or marketed products as part of any other clinical study within 30 days (or 5 half-lives whichever is longer) prior to screening (Visit 1), 22. Patient is unable or unwilling to co-operate with the study procedures. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline after 14-days treatment in objective daytime cough frequency on XEN-D0501 compared to placebo. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Change from baseline after 14 days treatment for XEN D0501 compared to placebo for the following parameters: - capsaicin cough response (Emax) - objective 24-hour cough frequency - hourly change in cough frequency - cough severity (VAS) - urge to cough (VAS) - Leicester Cough Questionnaire Difference between XEN-D0501 and placebo after 14 days treatment for : - Global rating of change scale. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |